Skip to content

Sancai granule improves lung and kidney function for patient with novel coronavirus pneumonia (COVID-19) in the recovery period: a randomized, parallel controlled trial

Sancai granule improves lung and kidney function for patient with COVID-19 pneumonia in the recovery period: a randomized, parallel controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034794
Enrollment
Unknown
Registered
2020-07-19
Start date
2020-05-01
Completion date
Unknown
Last updated
2020-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

Hubei Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who met the discharge standards with the criteria for Diagnosis and Treatment Guideline of Novel Coronavirus Pneumonia (Trial 7th edition) and have a negative nucleic acid test for the new coronavirus after discharge 2. lung CT showed inflammation in the lungs or manifestations of pulmonary fibrosis in the past 1 week; 3. Aged 18-70 years old; 4. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who have had lung surgery that affects lung function; 2. Those who rely on mechanical ventilation to maintain lung function; 3. Combined with chronic lung and kidney disease affecting lung and kidney function; 4. Combined with diseases that affect heart function; 5. Accompanied by serious underlying diseases that affect survival; 6. Resting heart rate> 120/min; 7. Systolic blood pressure>180mmHg, diastolic blood pressure>100mmHg; 8. Severely obese people (BMI>30kg/m2); 9. People with allergies who allergic to the medicine components involved in the treatment plan; 10. Women who are pregnant or breastfeeding; 11. People with physical disabilities who cannot complete the collection of efficacy evaluation indicators; 12. Mentally unable to cooperate; 13. Participating in other clinical trials; 14. The investigator judges the patients that affect the efficacy and safety assessment.

Design outcomes

Primary

MeasureTime frame
recovery rate of pulmonary function;recovery rate of renal function;

Secondary

MeasureTime frame
six-minute walk test;pulmonary function recovery time;clinical symptoms;Lung CT recovery rate and recovery time;Novel coronavirus nucleic acid and antibody changes;immune change;Tongue coating evaluation;

Countries

China

Contacts

Public ContactBa Yuanming

Hubei Hospital of Traditional Chinese Medicine

1723426138@qq.com+86 13871013338

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026